VolitionRX Ltd (NYSEMKT:VNRX) received a $10.00 price target from HC Wainwright in a research report issued on Friday. The brokerage currently has a “buy” rating on the medical research company’s stock. HC Wainwright’s target price points to a potential upside of 249.65% from the stock’s previous close.

Shares of VolitionRX (NYSEMKT:VNRX) opened at 2.86 on Friday. The company’s market cap is $75.39 million. The company has a 50 day moving average of $3.24 and a 200-day moving average of $3.79. VolitionRX has a 12-month low of $2.74 and a 12-month high of $5.86.

VolitionRX (NYSEMKT:VNRX) last issued its earnings results on Thursday, May 11th. The medical research company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. Equities research analysts anticipate that VolitionRX will post ($0.56) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “HC Wainwright Analysts Give VolitionRX Ltd (VNRX) a $10.00 Price Target” was reported by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/hc-wainwright-analysts-give-volitionrx-ltd-vnrx-a-10-00-price-target/1471761.html.

A hedge fund recently raised its stake in VolitionRX stock. Bank of New York Mellon Corp raised its stake in VolitionRX Ltd (NYSEMKT:VNRX) by 177.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,376 shares of the medical research company’s stock after buying an additional 19,414 shares during the period. Bank of New York Mellon Corp owned 0.12% of VolitionRX worth $108,000 at the end of the most recent reporting period.

About VolitionRX

VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.

Receive News & Ratings for VolitionRX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.